erymethionase / eryminase

Product Candidate / PROGRAM Drug substance Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3/ Pivotal EMA/FDA review Commercial Rights
erymethionase Methionine-γ-lyase Solid tumors  
eryminase Arginine deiminase Solid tumors  

In addition to L-asparaginase, the active ingredient in our lead product candidate eryaspase, we are leveraging our proprietary ERYCAPS technology to develop additional product candidates, encapsulating other therapeutic drug substances. Based on our preclinical research, we have identified two other Cancer Metabolism enzymes, methionine-γ-liase (MGL) and arginine deiminase (ADI), which we believe can benefit from being encapsulated in red blood cells. MGL and ADI degrade methionine and arginine respectively, two amino acids that are essential for tumor cells to survive and grow. erymethionase is currently in the end of preclinical development.